These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6513814)

  • 21. Role of alveolar macrophages in the neutrophil-dependent defense system against Pseudomonas aeruginosa infection in the lower respiratory tract. Amplifying effect of muramyl dipeptide analog.
    Ozaki T; Maeda M; Hayashi H; Nakamura Y; Moriguchi H; Kamei T; Yasuoka S; Ogura T
    Am Rev Respir Dis; 1989 Dec; 140(6):1595-601. PubMed ID: 2513762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl- L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice.
    Ishihara C; Iida J; Mizukoshi N; Yamamoto N; Yamamoto K; Kato K; Azuma I
    Vaccine; 1989 Aug; 7(4):309-13. PubMed ID: 2554602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of colony-stimulating factor from macrophages by muroctasin.
    Yamaguchi F; Akahane K; Takashi T; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):983-6. PubMed ID: 3263870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18).
    Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801
    [No Abstract]   [Full Text] [Related]  

  • 25. Adjuvant activity of mycoloyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in mice and guinea pigs.
    Uemiya M; Saiki I; Kusama T; Azuma I; Yamamura Y
    Microbiol Immunol; 1979; 23(8):821-3. PubMed ID: 120487
    [No Abstract]   [Full Text] [Related]  

  • 26. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
    Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonbacteremic pseudomonas pneumonia in immunosuppressed guinea pigs.
    Otani T; Katami K; Une T; Osada Y; Ogawa H
    Microbiol Immunol; 1982; 26(1):67-76. PubMed ID: 7087802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutagenicity studies of muroctasin.
    Shimada H; Hattori C; Sato T
    Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific binding sites of muroctasin on murine macrophages.
    Akasaki M; Masayasu H; Tsukada W; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):978-80. PubMed ID: 3190804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of plasma fibronectin production in mice by muroctasin.
    Endo N; Okuda T; Osada Y; Zen-Yoji H
    Arzneimittelforschung; 1988 Jul; 38(7A):997-8. PubMed ID: 3190806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biotransformation of muroctasin in mice.
    Matsubayashi K; Takegoshi T
    Arzneimittelforschung; 1988 Jul; 38(7A):1015-8. PubMed ID: 3190793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulation of nonspecific host resistance to infection induced by muramyldipeptides.
    Matsumoto K; Ogawa H; Nagase O; Kusama T; Azuma I
    Microbiol Immunol; 1981; 25(10):1047-58. PubMed ID: 7031443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A synthetic adjuvant effective in inducing antitumor immunity.
    Kataoka T; Tokunaga T
    Jpn J Cancer Res; 1988 Jul; 79(7):817-20. PubMed ID: 3139596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local tolerance of muroctasin injection in rabbits.
    Nakashima K; Jindo T; Nomura M
    Arzneimittelforschung; 1988 Jul; 38(7A):1038-9. PubMed ID: 3190798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical modification of the C-6 substituent in the carbohydrate moiety of N-acetylmuramoyl-L-alanyl-D-isoglutamine (MDP), and the immunoadjuvant activity.
    Okumura H; Tokushima Y; Saiki I; Azuma I; Kiso M; Hasegawa A
    Carbohydr Res; 1983 Oct; 122(1):87-98. PubMed ID: 6652634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity on line 10 hepatoma in strain 2 guinea pigs and pharmaceutical properties of quinonyl-MDP preparations.
    Azuma I; Ogawa Y; Igari Y; Ukei S; Yamamura Y
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):15-8. PubMed ID: 3702541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restorative effect of MDP-Lys (L18) on leukopenia of cancer patient treated with radiotherapy.
    Okawa T; Kikuchi Y; Watarai J; Dokiya T; Tanaka T; Saito Y; Hirokawa Y; Takegawa Y; Hata K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Apr; 48(4):514-22. PubMed ID: 3231516
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis and immunoadjuvant activity of N-[2-O-(2-acetamido- 1,2,3,5-tetradeoxy-1,5-imino-D-glucitol-3-yl)-D-lactoyl]- L-alanyl-D-isoglutamine.
    Ishida H; Kitagawa M; Kiso M; Hasegawa A; Azuma I
    Carbohydr Res; 1990 Dec; 208():267-72. PubMed ID: 2085813
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunostimulant activity in conformationally constrained analogues of MDP.
    Kundu B; Rizvi SY; Haq W; Saxena RP; Saxena KC; Mathru KB
    Indian J Biochem Biophys; 1987 Jun; 24(3):129-32. PubMed ID: 3428910
    [No Abstract]   [Full Text] [Related]  

  • 40. Studies on the stability of muroctasin and degradation products built under extreme conditions.
    Moroi R; Yamazaki K; Hirota T; Watanabe S; Oki M; Toriyama M; Ichinohe A; Kataoka K
    Arzneimittelforschung; 1988 Jul; 38(7A):959-68. PubMed ID: 3190803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.